240 related articles for article (PubMed ID: 17822770)
1. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study.
Sharpe MD; Ghent C; Grant D; Horbay GL; McDougal J; David Colby W
Transplantation; 2003 Sep; 76(6):977-83. PubMed ID: 14508365
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
4. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.
Romero AJ; Le Pogamp P; Nilsson LG; Wood N
Clin Pharmacol Ther; 2002 Apr; 71(4):226-34. PubMed ID: 11956505
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Rotstein C; Bow EJ; Laverdiere M; Ioannou S; Carr D; Moghaddam N
Clin Infect Dis; 1999 Feb; 28(2):331-40. PubMed ID: 10064252
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
12. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
[TBL] [Abstract][Full Text] [Related]
14. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.
Menichetti F; Del Favero A; Martino P; Bucaneve G; Micozzi A; Girmenia C; Barbabietola G; Pagańo L; Leoni P; Specchia G; Caiozzo A; Raimondi R; Mandelli F
Clin Infect Dis; 1999 Feb; 28(2):250-5. PubMed ID: 10064240
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand.
Chariyalertsak S; Supparatpinyo K; Sirisanthana T; Nelson KE
Clin Infect Dis; 2002 Jan; 34(2):277-84. PubMed ID: 11740718
[TBL] [Abstract][Full Text] [Related]
19. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
McKinsey DS; Wheat LJ; Cloud GA; Pierce M; Black JR; Bamberger DM; Goldman M; Thomas CJ; Gutsch HM; Moskovitz B; Dismukes WE; Kauffman CA
Clin Infect Dis; 1999 May; 28(5):1049-56. PubMed ID: 10452633
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
